New Vaccines for Global Health. Adrian Hill The Jenner Institute, Oxford University
|
|
- Gary Price
- 5 years ago
- Views:
Transcription
1 New Vaccines for Global Health Adrian Hill The Jenner Institute, Oxford University
2 1796: Jenner Invents Vaccination Edward Jenner DM (Oxon)
3 Synergies in Human and Livestock Vaccine Development Same or related diseases in two species e.g. tuberculosis, influenza Rapid efficacy testing in large animal species allowing biomarker identification Large animals better predictors of immunogenicity Common novel technology platforms Similar cost constraints for low income markets But until now largely independent development
4
5 Malaria Mortality and Morbidity Currently about 900,000 deaths each year from Plasmodium falciparum Mostly in young children Mostly in Africa About 250,000,000 clinical cases a year Malaria control now costing $2 billion annually Tools such as spraying, drugs and impregnated bed nets have a finite period of utility Current economic cost of malaria to Africa : ~$12bn
6 A Complex Parasite Life-Cycle Many Target Antigens
7 Transmission Blocking Vaccines Parasite Candidate Antigens Pfs48/45 Pfs230 Pfs25 PfsHAP2 Pfs48/45 Pfs230 a: Expressed in host b: Expressed in vector
8 Transmission Blocking Vaccines Mosquito Vector Candidate Antigens Alanyl Aminopeptidase N1: a mosquito midgut receptor mosquito midgut antigen transmission blocking activity against multiple parasite species most Anopheles vectors appear susceptible
9 Blood-Stage Malaria Vaccines
10 Leading Blood-Stage Malaria Antigens Most natural immunity targets blood-stage Multiple target antigens are available A major target, PfEMP1, shows antigen variation Many show substantial polymorphism
11 Blood-Stage Vaccine Trials Phase Vaccine name Blood-stage Antigen(s) Allele(s) Adjuvant Lead Author Year GIA Efficacy Population Ia AMA1-C1 AMA1 3D7 + FVO M ISA 720 Pierce 2010 Yes (up to 65%) Not assessed Australian adults Ia AMA1-C1 AMA1 3D7 + FVO Alhydrogel Malkin 2005 Yes (up to 54%) Not assessed US adults Ia AMA1-C1 AMA1 3D7 + FVO Alhydrogel + CpG7909 Ellis 2009 Yes (up to 97%) Not assessed US adults Ia AMA1-C1 AMA1 3D7 + FVO Alhydrogel + CpG7909 Mullen 2008 Y (up to 96%) Not assessed US adults Ia Pf(3D7)AMA1 AMA1 3D7 M ISA 720 Saul 2005 Not assessed Not assessed Australian adults Ia AMA1 FVO AMA1 FVO Alhydrogel/ M ISA720 /AS02 Roestenberg 2008 Yes Not assessed Dutch adults Ia FMP2.1 AMA1 3D7 AS02A Polhemus 2007 Yes (median up to 17%) Not assessed US adults Ia MSP1-C1 MSP1 3D7 + FVO Alhydrogel plus CpG7909 Ellis 2010 Y (up to 32%) Not assessed US adults Ia FMP1 MSP142 3D7/FVO Alhydrogel Malkin 2007 Y (< 20%) Not assessed US adults Ia FMP1 MSP142 3D7 AS02A Ockenhouse 2006 Y (<25%) Not assessed US adults Ia FMP1 MSP142 3D7 AS01B Start 2008 Ia Combination B MSP1/MSP2/SERA 3D7 M ISA 720 Saul 1999 Not assessed Not assessed Australian adults Ia P30P2 MSP-119 MSP119 3D7 or FVO Alum Keitel 1999 Not assessed Not assessed US adults Ia MSP3-LSP MSP3 Conserved Alum/ M ISA 720 Audran 2005 Not assessed Not assessed Swiss adults Ia GMZ2 GLURP/MSP3 Conserved Alum Esen 2009 Not assessed Not assessed German adults Ia PfCP2.9 AMA1/MSP119 3D7 + FVO M ISA 720 Hu 2008 No Not assessed Chinese adults Ia PfCP2.9 AMA1/MSP119 3D7 + FVO M ISA 720 Malkin 2008 Yes (up to 13%) Not assessed Chinese adults Ia PfCA AMA1 3D7 AdHu5 NIAID Unpublished Not known Not assessed US adults Ib AMA1-C1 AMA1 3D7 + FVO Alhydrogel + CpG7909 Sagara 2009 FVO only (<10% Not assessed Malian adults increase) Ib AMA1-C1 AMA1 3D7 + FVO Alhydrogel Dicko 2008 Not assessed Not assessed Malian children Ib AMA1-C1 AMA1 3D7 + FVO Alhydrogel Dicko 2007 No Not assessed Malian adults Ib FMP2.1 AMA1 3D7 AS02A Thera 2008 Yes (median < 40%) Not assessed Malian adults Ib FMP1 MSP142 3D7 AS02A Thera 2006 Not assessed Not assessed Malian adults Ib FMP1 MSP142 3D7 AS02A Stoute 2007 Not assessed Not assessed Kenyan adults Ib Combination B MSP1/MSP2/SERA 3D7 M ISA 720 Genton 2000 Not assessed Not assessed PNG adults Ib Combination B MSP1/MSP2/SERA 3D7 M ISA 720 Genton 2003 Not assessed None PNG children Ib MSP3-LSP MSP3 Conserved Alum Lusingu 2009 Not assessed Not assessed Tanzanian children Ib MSP3-LSP MSP3 Conserved Alum Sirima 2007 Not assessed Not assessed Burkina Faso adults Ib MSP3-LSP MSP3 Conserved Alum Nebie 2009 Not assessed Not assessed Burkina Faso adults I/IIa FMP2.1 AMA1 3D7 AS02A vs AS01B Spring 2009 Yes (mean 3D7 up to Some US adults 30%) I/IIa PEV3A AMA1 Conserved Virosome Thompson 2008 No Some UK adults I/IIa NYVAC-Pf7 MSP1, AMA1, SERA 3D7 NYVAC Ockenhouse 1998 Not assessed Some US adults IIa Combination B MSP1/MSP2/SERA 3D7 M ISA 720 Lawrence 2000 Not assessed None Australian adults I/IIb SPf66 83, 55, 35 kda Alum Cochrane Not assessed Some (South South America, peptides Review America) Africa, Asia IIb AMA1-C1 AMA1 3D7 + FVO Alhydrogel Sagara 2009 Not assessed None Malian children IIb FMP1 MSP142 3D7 AS02 Ogutu 2009 Not assessed None Kenyan children IIb Combination B MSP1/MSP2/SERA 3D7 M ISA 720 Genton 2002 Not assessed Some PNG children
12 Pre-Erythrocytic Malaria Vaccines Sporozoite and Liver-stages Mosquito bites protect! Irradiated parasites >1000 bites required Effective in mice, fowl, monkeys, humans Known since 1970s Irradiation can now be replaced by genetic alteration of parasites
13 SANARIA The quest for a whole sporozoite vaccine
14 Difficulties for the Whole Irradiated Sporozoite Vaccine Approach Manufacturing One batch per day Storage Liquid nitrogen required Lack of efficacy with 137,000 parasites x 6
15 Killer T-Cell Attack on an Infected Liver Cell Parasites Liver Cell HLA = Killer T Cell Human Leucocyte Antigen P Receptor Cytoplasm KILLING
16 The MeTRAP Vaccine Insert Targets the Liver-Stage of Plasmodium falciparum A Polyepitope-Protein Vaccine Construct ME: Multiple malaria Epitopes TRAP: Thrombospondin- Related Adhesion Protein TRAP strain is T9/96 in this vaccine
17 Why Use Viral Vectors in Prime-Boost Regimes? Best means of safely inducing T cells in humans Only 5 vaccines have induced >1000 SFU/ml in malaria (x 3), tuberculosis and influenza all used viral vector boosting Adenovirus MVA is the most potent approach better than DNA Adenovirus better than Adenovirus - Heterologous Ad Adenovirus Prime 8 weeks MVA Boost
18 Viral Vector Vaccines to Maximise Cellular Immunogenicity 8 weeks Adenovirus Prime MVA Boost Malaria, HCV, HIV, influenza, TB...
19
20 Vectored Liver-Stage Vaccines for Malaria Efficacy correlated with CD8 T cell numbers in phase II trials First example for any vaccine Excellent safety data for both adenovirus and MVA vectored vaccines Phase I trials of AdCh63-MVA completed successfully in Kenya and The Gambia
21 The RTS,S Malaria Vaccine Candidate
22 RTS,S Sporozoite Challenge Typically Shows 60% Sterile or Partial Protection RT
23
24 A Sporozoite and Liver-Stage Vaccine a combination two-hit approach Sporozoite Stage: Antibodies clear most sporozoites schizonts Liver Stage: T Cells clear the remaining liver cells RBC
25 RTS,S + Vectored TRAP an infant immunisation regime A Simple Regime for Deployment in Developing Countries through the Expanded Programme on Immunisation months R+A R+A R+M R = RTS,S/AS01 A = AdCh63 MeTRAP M = MVA MeTRAP
26 Sukuta Vaccine Clinic The Gambia
27 Conclusions Pre-erythrocytic malaria vaccines have shown most efficacy in humans clinical trials Blood-stage vaccines have been more difficult Sexual and mosquito stage vaccines just starting in the clinic Both RTS,S and vectored vaccines now show efficacy in most people on sporozoite challenge Through antibodies and CD8 T cells, respectively RTS,S shows efficacy of ~40% in field trials Now in a large phase III licensure trial A combination approach with vectors + RTS,S would probably show much higher efficacy
28 Jenner Institute Laboratories OLD ROAD CAMPUS RESEARCH BUILDING
29 Churchill Hospital Facilities Centre for Clinical Vaccinology and Tropical Medicine Clinical Biomanufacturing Facility
30 Vaccine Trial Partners in Africa Wellcome-KEMRI, Kilifi, Kenya University of Cape Town, South Africa MRC Laboratories, The Gambia University of Nairobi, Kenya Université Cheikh Anta Diop, Senegal CNRFP, Ouagadougou, Burkina Faso
31 Three Priorities for the Jenner Institute Global Health vaccines that make a difference HIV, TB, malaria, dengue, pandemic influenza Translational Research rapid early clinical testing 28 vaccines made for clinical trials One Health vaccines for humans and other animals
32 Estimated tuberculosis incidence rates 2008
33 Epidemiology of TB in the 21 st Century 8.8 million new cases per annum 1.7 million deaths per annum Resistance MDR-TB XDR-TB Overlap with HIV epidemic Burden of latent infection
34 Global Plan to Stop TB: Targets (from Millenium Development Goals) > 70% with infectious TB will be diagnosed > 85% of those will be cured By 2015, global prevalence of TB will be reduced to 50% of 1990 levels By 2050, global incidence will be < 1/ million population How? Use of current tools DOTS; DOTS-plus; DOTS expansion New tools New drugs New diagnostics New vaccines Total cost of plan: $56 billion so a $31 billion funding gap
35 Bacille Calmette-Guerin Live attenuated Mycobacterium bovis First used in 1921 (orally) 2 big trials in 1950s: UK (Copenhagen strain, highly effective) US (Tice strain, no effect)
36 Efficacy of BCG Good Disseminated TB and TB meningitis Leprosy Bad Lung disease at any age Boosting (Rodrigues et al, Lancet 2005)
37 New TB Vaccines in the Clinic Vaccine Developer What Clinical Stage Type rbcg30 UCLA Recombinant BCG overexpressing Ag85B I - ended Mycobacterial rbcgδurea::hly VPM Recombinant BCG expressing Lysteriolysin I Mycobacterial M72 in AS01 GSKBio Subunit fusion protein of Rv1196 and Rv0125 in ASO1 adjuvant I Protein in adjuvant 85B-ESAT6 in IC31 (Hyb1) SSI Subunit fusion protein of Ag85B and ESAT6 in IC31 adjuvant I Protein in adjuvant 85B-TB10.4 in IC31 (HyVAC4) SSI Subunit fusion protein of Ag85B and TB10.4 in IC31 adjuvant I Protein in adjuvant rad35-ag85a, 85B,TB10.4 Crucell Recombinant adenovirus35 expressing Ag 85A, 85B, 10.4 Ib Viral vector MVA85A Oxford University / OETC Recombinant vaccinia expressing Ag85A IIb Viral vector
38 MVA85A Expresses a major gene from Mycobacterium tuberculosis Made in Oxford in 1999 Replication-impaired First clinical trial in Oxford in 2002 Now 14 completed clinical trials In the UK, The Gambia, Senegal, South Africa Remarkable CD4 T cell potency The most advanced new TB vaccine in clinical development Helen McShane
39 BCG / MVA85A: Enhanced Protection In The Lungs of M. Bovis Infected Calves Dunn s: *, p < 0.05; **, p < 0.01 Vordermeier et al. 2009
40 Summary of Clinical Trials with MVA85A since 2002
41 BCG MVA85A induces High and Sustained Antigen 85A-Specific Immune Responses in UK Vaccinees * * p<0.05 ** p<0.01 SFC / 10^6 PBMC ** ** * BCG MVA85A BCG- MVA85A Time (weeks) McShane et al, Nature Medicine 2004
42 MVA85A Induced Antigen Specific CD4+ T Cells Are Highly Polyfunctional Pre-MVA85A Wk 1 Wk 2 Wk 8 Wk 24 Pre-MVA85A Wk 1 Wk 2 Wk 8 Wk 24 Number of functions: Beveridge N et al, EJI 2007
43 MVA85A Target Indications Booster vaccine administered in infancy (4-6 months) Booster vaccine administered to HIV+ at diagnosis Booster vaccine administered in adolescence i.e. 3 possible efficacy trials If effective, MVA85A would be indicated anywhere in the world where BCG is used But you need a high incidence area to test efficacy
44
45 Infant Phase IIb Efficacy Trial Objectives: Safety Immunogenicity Efficacy (against disease & infection) Immune correlates Design: BCG vaccinated infants in Worcester, South Africa Randomised at weeks to receive either: MVA85A (1 x 10 8 pfu) placebo (Candin) Sample size = 2784 (1392/arm) Cumulative TB incidence of 3% 90% power to detect 60% improvement over BCG alone Oxford + Emergent BioSolutions: Oxford Emergent Tuberculosis Consortium - with Wellcome Trust and Aeras Global TB Vaccine Foundation funding - collaboration with University of Cape Town
46 Phase IIb Efficacy Trial of MVA85A in HIV-Infected Adults Proof of concept study in HIV+ adults protection against TB disease protection against M. tb infection safety & immunogenicity Two sites South Africa: Cape Town with R Wilkinson Senegal: Dakar with S Mboup Sponsored by Aeras Global TB Vaccine Foundation Funded by EDCTP, MRC and Aeras Due to start in May 2011
47 Global Distribution of HIV Strains B B B A C E C C 32 million people are living with HIV infection, mainly in Africa
48 Synthetic HIV CONSV Vaccine C D A B C D A B C D A B C D Gag Pol Vif Env Mamu-A*01 epitope H-2D d & L d epitope mab epitope Pk Humanized codons AdCh63 attenuated adenoviruses MVA attenuated poxvirus Tom Hanke, Lucy Dorrell, Andrew McMichael
49 A New Cross-Strain Influenza Vaccine targets the internal antigens of flu these are conserved between human and avian viruses excellent phase I safety and immunogenicity
50 The Influenza A Virus Virion Two surface glycoproteins - haemagglutinin (HA) - neuraminidase (NA) Embedded M2 protein The ribonucleoprotein complex - nucleoprotein (NP) - three polymerase proteins - matrix (M1) protein.
51 FLU002- a Phase IIa Efficacy Trial Collaboration with Retroscreen Virology Ltd. Screen healthy volunteers for low anti-flu antibodies Challenge all intranasally 4 weeks after vaccination date, in a contained facility Monitor viral shedding and symptoms for 10 days All given oseltamivir prior to leaving containment 51
52 Enhancing the Immunogenicity and Efficacy of Vectored Vaccines Grand Challenge 5: Solve how to design antigens for effective, protective immunity
53 The HydRIS System Glass stabilisation of vaccines on a membrane
54 Bioengineering Technologies for Vaccine Delivery Microneedle array Stratum corneum (10-20µm) Epidermis Dermis Nerve Sweat gland Hair follicle Subcutaneous layer
55 Funders JENNER VACCINE FOUNDATION
56 Key Contributors Helen McShane Sarah Gilbert Simon Draper Andrew McMichael Tuberculosis Influenza Malaria HIV Babatunde Imoukhuede, Souleyman Mboup, Greg Hussey, Kevin Marsh, Tumani Corrah
Global progress in vaccine development
Global progress in vaccine development Helen McShane The Jenner Institute University of Oxford helen.mcshane@ndm.ox.ac.uk Vaccination The most cost-effective health intervention Smallpox Poliomyelitis
More informationUpdate on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town
Update on TB Vaccines Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town 1 Robert Koch s Therapeutic TB vaccine 1890: Purified Tuberculin Protein 1891: First negative reports
More informationPerspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis
Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Existing TB Vaccine is not effective for global TB epidemic control BCG
More informationMalaria parasite vaccine development Strategies & Targets
Malaria parasite vaccine development Strategies & Targets Tulane University Ahmed Aly Most malaria disease deaths are among children and pregnant women A child or a pregnant woman dies of malaria nearly
More informationDevelopment of a Universal T Cell Vaccine. Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom
Development of a Universal T Cell Vaccine Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom Development of HIV-1 vaccines Induction of cell-mediated responses Immunogens
More informationTB Vaccine Development Strategy Overview
TB Vaccine Development Strategy Overview October 28, 2014 Angeline Nanni, MBA, MS Aeras Director, Global Access TB is Mother Nature s number one killer over the past centuries TB is spread through the
More informationChallenging the Current Malaria Vaccine Pipeline. Dr Odile LEROY Basel 6th December 2016
Challenging the Current Malaria Vaccine Pipeline Dr Odile LEROY Basel 6th December 2016 1 Malaria Burden Notable progresses but still major public health issue 214 million new cases 18% decline in 15 years
More informationTB Vaccine Research and Development: Progress, Strategies and Controversies
15 March 2016 GVIRF Global Forum Johannesburg, South Africa TB Vaccine Research and Development: Progress, Strategies and Controversies Lewis Schrager, M.D. V.P., Scientific Affairs Rockville, MD USA Source:
More informationTB vaccine progress. Hassan Mahomed. Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health,
TB vaccine progress Hassan Mahomed South African TB Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health, University of Cape Town, South
More informationReview on vectored influenza vaccines. Sarah Gilbert Jenner Institute Oxford
Review on vectored influenza vaccines Sarah Gilbert Jenner Institute Oxford Viral Vectored Influenza Vaccines Can be used to induce antibodies against HA Will also boost CD4 + T cell responses against
More informationNew Tuberculosis Vaccines Developmental Strategies
New Tuberculosis Vaccines Developmental Strategies Michael Brennan, Ph.D. Aeras SAGE Geneva, Switzerland 10 November 2011 The Potential of New TB Vaccines A new, more effective TB vaccine could: Be safer
More informationEnhancing Immunogenicity of Recombinant Vaccines: Chemical Conjugation
Enhancing Immunogenicity of Recombinant Vaccines: Chemical Conjugation Malaria vaccine development and a role for conjugates Ashley J Birkett, PhD Director, Research & Development New Cells, New Vaccines
More informationUpdate on Tuberculosis Vaccines
March 27, 2014 Update on Tuberculosis Vaccines - 2014 Tom Evans MD CEO, Aeras TB is Mother Nature s AERAS GLOBAL number TB VACCINE one FOUNDATION killer over the past centuries TB is spread through the
More informationProgress and Challenges in Malaria Vaccines
Progress and Challenges in Malaria Vaccines Vasee Moorthy MD PhD Initiative for Vaccine Research, WHO Geneva 1 SKIN STAGE VIDEOS 1 Hour: IgG 2 1 Hour: IgG 6 Days: CD8 7 Days: IgG Passive: IgG NATURAL IMMUNITY
More informationTuberculosis The Race for a Cure
Tuberculosis The Race for a Cure Kari Stoever Faster Cures Annual Conference November 4, 2013 Aeras: A non profit biotech advancing TB vaccines for the world Founded in 2003 in-house capabilities in finance,
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationUpdate on TB Vaccines
Update on TB Vaccines Hennie Geldenhuys 11 May 2012 A safe and effective TB Vaccine within a decade A Strategic Blueprint for the Next Decade Tuberculosis, Vol 92, March 2012, Suppl. 1, pgs S1-S35 On
More informationMalaria Vaccine Pipeline
Malaria Vaccine Pipeline Perspectives and Challenges Carla Botting World Vaccine Congress Asia 2008 3 June 2008 Discussion Points Scope of the problem: the burden and challenge of malaria Malaria vaccine
More information1 introduction strengthening and ac- celerating future vaccine innovation and development for diseases of poverty.
European Vaccine Initiative 1 Introduction Infectious diseases are key contributors to the devastating poverty in much of the world today. Every year diseases of poverty kill almost 9 million people, many
More informationMalaria. Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania
Malaria Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania Despite 42% reduction since 2000, a child dies every minute in Africa from malaria 207 million malaria cases in 2012,
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationAdvances and challenges in malaria vaccine development
Science in medicine Advances and challenges in malaria vaccine development Peter D. Crompton, 1 Susan K. Pierce, 1 and Louis H. Miller 2 1 Laboratory of Immunogenetics and 2 Laboratory of Malaria and Vector
More informationMalaria vaccines where are we now?
Malaria vaccines where are we now? Lars Hviid (lhviid@sund.ku.dk) Centre for Medical Parasitology Department of Immunology and Microbiology Slide 1 Background: A very interested but disinterested real
More informationMalaria. Edwin J. Asturias, MD
Malaria Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public Health Global Health and Disasters Course
More informationBiomedical Engineering for Global Health. Lecture 10 HIV/AIDS vaccine development
Biomedical Engineering for Global Health Lecture 10 HIV/AIDS vaccine development Review of lecture 9 How do vaccines work? Types ofvaccines: Review of lecture 9 Are vaccines effective? -Edward Jenner s
More informationPartnerships in TB Vaccine Research & Development. James E. Connolly President & CEO Aeras Global TB Vaccine Foundation
Partnerships in TB Vaccine Research & Development James E. Connolly President & CEO Aeras Global TB Vaccine Foundation Aeras Mission & GLOBAL the TB VACCINE PDP FOUNDATION Model Develop new, more effective
More informationDeveloping TB Vaccine Clinical Trial Capacity Aeras Perspective. Vicky Cardenas, PhD, JD
Developing TB Vaccine Clinical Trial Capacity Aeras Perspective Vicky Cardenas, PhD, JD ASEAN-EU STI Days 21-23 January 2014 Aeras Founded in 2003 Mission: Develop improved TB vaccines that are affordable
More informationStatus of RTS,S/AS01 malaria vaccine candidate
Status of RTS,S/AS01 malaria vaccine candidate Multi-center RTS,S malaria vaccine efficacy trial Phase 3, randomized, controlled, double-blind trial conducted in 11 centers in 7 African countries 15,460
More informationVaccines against malaria
Vaccines against malaria Adrian V. S. Hill Phil. Trans. R. Soc. B 2011 366, 2806-2814 doi: 10.1098/rstb.2011.0091 Supplementary data References Subject collections Email alerting service "Audio Supplement"
More informationPartnering to Support Research Capacity in TB Endemic Countries
Partnering to Support Research Capacity in TB Endemic Countries Dr. Tony Hawkridge Aeras Global TB Vaccine Foundation, Africa Office Fifth EDCTP Forum 13 October 2009 Arusha, Tanzania Invention of BCG
More informationMonitoring tuberculosis progression using MRI and stereology
Monitoring tuberculosis progression using MRI and stereology TB the problem Estimated number of new cases in 2007 2 million deaths; 9 million new cases p.a. TB kills someone every 15 secs, 9,153 cases
More informationOf mice and men: practical approaches to malaria vaccine discovery and development
Of mice and men: practical approaches to malaria vaccine discovery and development --> The consequences of the screen employed to identify a parasite molecule as a «major vaccine candidate «Or the problem
More informationBRIEFING ON RTS,S/AS01 MALARIA VACCINE FOR THE SEPTEMBER 2012 MEETING OF MPAC
BRIEFING ON RTS,S/AS01 MALARIA VACCINE FOR THE SEPTEMBER 2012 MEETING OF MPAC Introduction Date: 12 August 2012. Author: WHO Secretariat with input from JTEG Chair The most advanced vaccine candidate against
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationTB Vaccine Development Status: Review of Critical Issues and Selected Candidates in Phase 2 or Phase 3
TB Vaccine Development Status: Review of Critical Issues and Selected Candidates in Phase 2 or Phase 3 22 June 2017 WHO PD-VAC Geneva, Switzerland Lewis K. Schrager, M.D. North Bethesda, MD USA Outline
More informationInfluenza vaccinology and clinical assessment
DEPARTMENT OF INFECTION AND IMMUNITY Influenza vaccinology and clinical assessment In support of submission for the degree of Doctor of Philosophy (Ph.D.) Dr Patrick John Lillie June 2014 Table of Contents
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationHow does the body defend itself?
Prevention of Infection 2 Immunisation 3 rd BDS B. Martin Major World Causes Of Death COUNTRIES Developing Developed Total x10-6 Population 5400 (80%) 1200 (20%) 6600 CAUSE OF DEATH % % % Infectious diseases
More informationPress Release: Embargo in place until Monday, February 19 th, 2018 I 6:00 Eastern standard Time (11GMT)
Press Release: Embargo in place until Monday, February 19 th, 2018 I 6:00 Eastern standard Time (11GMT) Results from innovative tuberculosis vaccine trial show potential for new BCG revaccination strategies
More informationEVIDENCE SYNTHESIS FOR GLOBAL HEALTH: ANIMAL STUDIES UNDER THE LENS
EVIDENCE SYNTHESIS FOR GLOBAL HEALTH: ANIMAL STUDIES UNDER THE LENS Paul Garner On behalf of the Cochrane infectious Diseases Group Editors And the Effective Health Care Research Programme Consortium Competing
More informationIntroduction. In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology.
Introduction In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology. - Genomics: fasten antigen discovery for complex pathogens
More informationMalaria and vaccination: an update. Robert Sauerwein Dept. of Medical Microbiology Radboud University Medical Center, Nijmegen, the Netherlands
Malaria and vaccination: an update ) Robert Sauerwein Dept. of Medical Microbiology Radboud University Medical Center, Nijmegen, the Netherlands Malaria Control Drugs for treatment and/or prophylaxis Artemisinin-based
More informationUrgent Need for Global Investment in TB Vaccines. Stop TB Partnership Board Meeting Jacqueline E. Shea, PhD Chief Executive Officer Aeras
Urgent Need for Global Investment in TB Vaccines Stop TB Partnership Board Meeting Jacqueline E. Shea, PhD Chief Executive Officer Aeras 2 We need a more effective vaccine than BCG 3 Global Strategies
More informationNew tools for control of bovine tuberculosis in cattle
New tools for control of bovine tuberculosis in cattle Bryce Buddle AgResearch, Hopkirk Research Institute Bovine tuberculosis (TB) in New Zealand Total cost of $100 million/year ($81 million TBfree NZ)
More informationDr Olga Pleguezuelos CSO and Project Manager at SEEK
Dr Olga Pleguezuelos CSO and Project Manager at SEEK Imutex Limited, formed in 2016, is a joint venture between SEEK Group and hvivo to accelerate the development of a Mosquito Vaccine (AGS-v) and Broad-
More informationModerate efficacy malaria vaccines as part of comprehensive malaria control and elimination
Moderate efficacy malaria vaccines as part of comprehensive malaria control and elimination Progress and Limitation of Existing Vector Control Tools Draper & Smith 1960 TRSTMH 54: 342 Cannot afford to
More informationProfessor Jonathan Weber
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Jonathan Weber Imperial College, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/35908 holds various files of this Leiden University dissertation Author: Soema, Peter Title: Formulation of influenza T cell peptides : in search of a universal
More informationEDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG. MBOUP Souleymane
EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG MBOUP Souleymane HIV VACCINE IN AFRICA In 2005, 13 new trials of preventive AIDS vaccine candidates began in 9
More informationTrends in vaccinology
Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March
More informationClinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More information#4 (Tuberculosis OR TB OR Pulmonary Tuberculosis OR Multi-Drug Resistant Tuberculosis OR MDR OR Extremely-Drug Resistant Tuberculosis or XDR)
DATABASE Cochrane Database of Systematic Reviews DATE 15 DECEMBER 2015 #1 Safety of Crucell Ad35/ AERAS-402 OR Effectiveness of Crucell Ad35/ Aeras-402 OR Safety of MVA85A/ Aeras-485 OR Effectiveness of
More informationDeliberate release of the GMO AdCh3NSmut1 in a proposed clinical trial
Environmental Risk Assessment Deliberate release of the GMO AdCh3NSmut1 in a proposed clinical trial Conducted according to the principles described in: S.I. No. 500 of 2003 Genetically Modified Organisms
More informationTB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director
TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition
More informationTBVAC2020. Advancing novel & promising TB vaccine candidates from discovery to preclinical/early clinical development
TBVAC2020 Advancing novel & promising TB vaccine candidates from discovery to preclinical/early clinical development Défis Scientifiques et Economiques du Développement de Vaccins pour les Pays du Sud
More informationTuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012
Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally
More informationSummary of Key Points WHO Position Paper on BCG Vaccine, February 2018
Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018 1 Introduction This position paper replaces the 2004 WHO position paper on Bacille Calmette-Guérin (BCG) vaccine and the 2007 WHO
More informationTitle Description. Presenter(s) Recording Keywords alumni, TB, tuberculosis, vaccinology, C550, 1 Part of series Alumni Weekend 2009
Title Description Developing an improved TB vaccine Dr McShane talks about the University s work in creating an improved vaccine against tuberculosis and she also talks about the urgency of this research
More informationNational Health & Medical Research Council (NHMRC) Results Fellowships and Australia/European Union Collaborative Grants Scheme 2018
National Health & Medical Research Council (NHMRC) Results Fellowships and Australia/European Union Collaborative Grants Scheme 2018 The NHMRC has publically released results (embargo lifted on 11 October
More informationPARTICIPANT INFORMATION SHEET: EBL04
Professor Adrian Hill E-mail: vaccinetrials@ndm.ox.ac.uk Tel: 01865 857406 INSERT LOCAL DETAILS NRES Committee South Central - Oxford A ref number:15/sc/0108 PARTICIPANT INFORMATION SHEET: EBL04 A study
More informationHIV, Tuberculosis, and Malaria JAN WILHELM
HIV, Tuberculosis, and Malaria JAN WILHELM 2 HIV, Malaria, and Tuberculosis HIV, Tuberculosis, and Malaria Jan Wilhelm, MD Professor of Pediatrics, Clínica Alemana Universidad del Desarrollo School of
More informationImmunology of TB and its relevance to TB Control
Immunology of TB and its relevance to TB Control W. Henry Boom, M.D. TB Research Unit Case Western Reserve University NIAID-DMID: -AI70022 Global TB Epidemiology 2009 < 10 10 to 24 25 to 49 50 to 99 100
More informationConfronting infectious diseases and the role of vaccination: A global perspective KATE ANTEYI. MD, MPH, MBA
Confronting infectious diseases and the role of vaccination: A global perspective KATE ANTEYI. MD, MPH, MBA Technical Advisor, United States Agency for International Development (USAID) Chair, WONCA Working
More informationOverview of the Malaria Vaccine Implementation Programme (MVIP) Prof. Fred Were SAGE meeting 17 April, 2018
Overview of the Malaria Vaccine Implementation Programme (MVIP) Prof. Fred Were SAGE meeting 17 April, 2018 1 Objectives Brief review Background EMA positive opinion and WHO recommendations Funding Description
More informationChapter 08 Lecture Outline
Chapter 08 Lecture Outline See separate PowerPoint slides for all figures and tables preinserted into PowerPoint without notes. Copyright 2016 McGraw-Hill Education. Permission required for reproduction
More informationNew Technology in Vaccine Engineering
Viruses in May Katoomba, August, 2012 New Technology in Vaccine Engineering Anton Middelberg Australian Institute for Bioengineering and Nanotechnology The University of Queensland, Australia Introduction
More informationRoadmaps as a Vehicle for Addressing Large- Scale Public Health Challenges: Lessons from the Malaria Vaccine Technology Roadmap
Background to development of vaccine roadmaps, to include priority areas for research, product development, capacities, and policy and commercialization Roadmaps as a Vehicle for Addressing Large- Scale
More informationAntimicrobial resistance Fact sheet N 194 Updated April 2014
Antimicrobial resistance Fact sheet N 194 Updated April 2014 Key facts Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by
More informationAOHS Global Health. Unit 1, Lesson 3. Communicable Disease
AOHS Global Health Unit 1, Lesson 3 Communicable Disease Copyright 2012 2016 NAF. All rights reserved. A communicable disease is passed from one infected person to another The range of communicable diseases
More informationNew Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine
More informationThe challenge of an HIV vaccine from the antibody perspective. Dennis Burton The Scripps Research Institute
The challenge of an HIV vaccine from the antibody perspective Dennis Burton The Scripps Research Institute AIDS Pandemic Nov 2005 North America 1.2 million [650 000 1.8 million] Caribbean 300 000 [200
More informationD-LAB HEALTH SP 725. Jose Gomez-Marquez
SP 725 Jose Gomez-Marquez 1 Vaccine Preventable Diseases Causes of 2.5 million child deaths out of 10.5 million child deaths globally, 2002 Source: WHO Wkly Epidemiol Rec. (2006) 81:189-196. 2 Rationale
More informationA Phase I Study to Assess the Safety of HIV and Hep C Vaccines Candidates When Given Separately or in Combination
A Phase I Study to Assess the Safety of HIV and Hep C Vaccines Candidates When Given Separately or in Combination Sponsor: University of Oxford EudraCT No.: 2014-000730-30 REC: South Central Oxford A REC
More informationVACCINATION IS PERHAPS THE
RESEARCH OPPORTUNITIES FOR SPECIFIC DISEASES AND DISORDERS Prospects for Vaccines to Protect Against AIDS, Tuberculosis, and Malaria Norman L. Letvin, MD Barry R. Bloom, PhD Stephen L. Hoffman, MD Given
More informationHow to be the Perfect Host. and How they deal with us
How to be the Perfect Host How we deal with viruses and How they deal with us 3 Parts Intro to viruses and immunity HCV making a vaccine HIV providing a cure What is a virus? A piece of bad news wrapped
More informationDevelopment of a Malaria Vaccine for Sub-Saharan African Children December 3, 2009 Lode Schuerman
Development of a Malaria Vaccine for Sub-Saharan African Children December 3, 2009 Lode Schuerman Copyright John-Michael Maas, Darby Communications Agenda Malaria Disease burden Prevention and vaccine
More informationTBVI the European Tuberculosis Vaccine Ininiative. Brigitte GICQUEL INSTITUT PASTEUR
TBVI the European Tuberculosis Vaccine Ininiative Brigitte GICQUEL INSTITUT PASTEUR Moving towards a TB free world in 2050 Foundation to facilitate European efforts Foundation to facilitate European efforts
More informationAddressing climate change driven health challenges in Africa
Addressing climate change driven health challenges in Africa Ednah N Ototo, Parasitologist, Climate Change and Health Kenyatta University, Kenya Kenya Medical Research Institute Outline The impact of climate
More informationVIR-2020: a CMV-based vaccine candidate for TB Aurelio Bonavia
VIR-2020: a CMV-based vaccine candidate for TB Aurelio Bonavia February 21, 2018, TB Global Forum, New Delhi, India INFECTIOUS DISEASES Massive Unmet Need 2,000,000,000 260,000,000 37,000,000 2,000,000
More informationKato, N. et al, Nature, 2016, Accelerated Article Preview. Celeste Alverez Current Literature 9/10/ /10/2016 Celeste Wipf Group 1
Kato, N. et al, Nature, 2016, Accelerated Article Preview Celeste Alverez Current Literature 9/10/2016 9/10/2016 Celeste Alverez @ Wipf Group 1 Malaria Caused by Plasmodium parasites Carried by 30-40 species
More informationJTEG s Summary of RTS,S/ AS01 Clinical Trial Data
JTEG s Summary of RTS,S/ AS01 Clinical Trial Data Peter Smith On behalf of the Joint Technical Expert Group (JTEG) based on Cohen et al 2010 RTS,S/AS01 Malaria Vaccine l Based on large segment of P. falciparum
More informationJournal of Infectious Diseases Advance Access published June 15, Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of
Journal of Infectious Diseases Advance Access published June 15, 2016 1 Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01 B with ChAd-MVA Vectored Vaccines Expressing
More informationPatricia Fitzgerald-Bocarsly
FLU Patricia Fitzgerald-Bocarsly October 23, 2008 Orthomyxoviruses Orthomyxo virus (ortho = true or correct ) Negative-sense RNA virus (complementary to mrna) Five different genera Influenza A, B, C Thogotovirus
More informationThe global tuberculosis (TB) epidemic. The Challenges Of Developing New Tuberculosis Vaccines. Fighting Critical Diseases
By Lewellys F. Barker, Annmarie E. Leadman, and Bartholt Clagett The Challenges Of Developing New Tuberculosis Vaccines doi: 10.1377/hlthaff.2011.0303 HEALTH AFFAIRS 30, NO. 6 (2011): 1073 1079 2011 Project
More informationPh.D. Thesis: Protective immune response in P.falciparum malaria 2011 CHAPTER I: Introduction. S.D. Lourembam 16
CHAPTER I: Introduction S.D. Lourembam 16 1. INTRODUCTION Malaria remains a major global health problem with 300 to 500 million clinical infections and more than a million deaths reported each year. In
More informationTB-VAC. An integrated project for the design and testing of vaccine candidates against tuberculosis: identification, development, and clinical studies
TB-VAC An integrated project for the design and testing of vaccine candidates against tuberculosis: identification, development, and clinical studies Tuberculosis-a worldwide problem 30 % of the world
More informationChildhood TB (and the mother-child dyad)
Childhood TB (and the mother-child dyad) Chairs: Mark Cotton and Lisa Nelson Rapporteur: Soumya Swaminathan Speakers Anneke Hesseling Philippa Musoke Amita Gupta Jerald Sadoff Over 2 million paediatric
More informationVaccines on the Global Scale
Vaccines on the Global Scale Learning from the past and aiming at the future Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health,
More informationA Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire.
Company LOGO A Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire. Fayaz Ahmad Mir, Stefan H. E. Kaufmann,
More informationAvian influenza and pandemic threats
Avian influenza and pandemic threats Philippe BUCHY MD, PhD Head of Virology Unit Director NIC Cambodia Vaccinology 2013 Bangkok, 11-13 November 2013 Influenza viruses Influenza viruses (Orthomyxoviridae)
More informationInfluenza. Influenza vaccines (WHO position paper) Weekly Epid. Record (2005, 80: ) 287
Program Management 82_19 SAGE encouraged all countries to consider their preparedness for a potential influenza pandemic, recognizing that it would occur before strain-specific vaccine can be made in significant
More informationPart One Immunology and Vaccination Strategies for AIDS and TB
Part One Immunology and Vaccination Strategies for AIDS and TB AIDS and Tuberculosis: A Deadly Liaison. Edited by Stefan H.E. Kaufmann and Bruce D. Walker Copyright Ó 2009 WILEY-VCH Verlag GmbH & Co. KGaA,
More informationPATH Influenza Vaccine Projects
PATH Influenza Vaccine Projects Overview John W. Boslego, MD John Boslego Director, Vaccine Development Global Program March 25 th, 2014 Influenza Vaccine Project (IVP) at PATH IVP Goal: Advance the development
More informationNIAID GL OBAL HEAL TH RESEAR CH PL AN FOR HIV/AIDS, MAL ARIA, AND TUBER CUL OSIS
NIAID GL OBAL HEAL TH RESEAR CH PL AN FOR HIV/AIDS, MAL ARIA, AND TUBER CUL OSIS M a y 7, 2 0 0 1 NA TIONAL INSTITUTE OF ALLER GY AND INFECTIOUS DISEASES NA TIONAL INSTITUTES OF HEAL TH U.S. DEP AR TMENT
More informationJournal of Asian Scientific Research
Journal of Asian Scientific Research ISSN(e): 2223-1331/ISSN(p): 2226-5724 URL: www.aessweb.com AN UPDATE ON NEW VACCINES FOR TUBERCULOSIS Afshan Sumera 1 --- Leong Chia Inn 2 --- Ankur Barua 3 1 Lecturer,
More informationBBS 2711 Virology. Virus Vaccines
BBS 2711 Virology Virus Vaccines Dr Paul Young, Department of Microbiology & Parasitology. p.young@mailbox.uq.edu.au Virus Vaccines First vaccine developed by Jenner in late 1700's against smallpox virus
More informationAd35.CS.01 RTS,S/AS01 prime boost second generation malaria vaccine candidate
Ad35.CS.01 /AS01 prime boost second generation malaria vaccine candidate Johan Vekemans MD, PhD Malaria vaccines Global Vaccine Development GSK Biologicals NIH 2012 1 The need for a malaria vaccine: targets
More information~~at. I h~.e read the amendment$ and agree that the trial \\'ill 00 conducted acc.ording ro I:he procedure-~ descri bed,
~~at I h~.e read the amendment$ and agree that the trial \\'ill 00 conducted acc.ording ro I:he procedure-~ descri bed,. This infoj:mation 11 tbc property of~t\'ï and ad righ15 are re$etved ~ F.MVJ pai\v11~li-fi-10
More informationApplication of Reverse Genetics to Influenza Vaccine Development
NIAID Application of Reverse Genetics to Influenza Vaccine Development Kanta Subbarao Laboratory of Infectious Diseases NIAID, NIH Licensed Vaccines for Influenza Principle: Induction of a protective
More informationMalaria. Population at Risk. Infectious Disease epidemiology BMTRY 713 (Lecture 23) Epidemiology of Malaria. April 6, Selassie AW (DPHS) 1
Infectious Disease Epidemiology BMTRY 713 (A. Selassie, DrPH) Lecture 23 Vector-Borne Disease (Part II) Epidemiology of Malaria Learning Objectives 1. Overview of malaria Global perspectives 2. Identify
More information